Ketamine Treatment Archives

2 minute read

Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA’s Stance, The Therapist’s Role & More

January 8, 3:33 PM

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.

OPTHF

4 minute read

Psyched: Defense Dept.’s Ketamine Trial, Cybin’s Psilocybin, Metabolic Disorders, Reform Update And More

By Lara Goldstein

December 5, 11:12 AM

Defense Dept. Funds Ketamine Study For PTSD Treatment

ATAI

2 minute read

Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans

By Lara Goldstein

November 27, 3:48 PM

A Department of Defense (DOD) Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans.

SEEL

2 minute read

Johnson & Johnson’s Q3 2023: $21.3B Rise In Sales, ‘Sharpened Focus’ On Innovation & Biotech Solutions

By Lara Goldstein

October 17, 2:28 PM

Healthcare company Johnson & Johnson (J&J) (NYSE: JNJ) shared its financial outcomes for the third quarter of 2023, reflecting:

JNJ

4 minute read

Psyched: FDA Warning, DEA’s Telehealth Extension, CA Gov’s Veto, Congress On Kratom, M&As & More

By Lara Goldstein

October 16, 3:57 PM

Cybin And Small Pharma Shareholders Green Light Acquisition Resolution

ATAI

1 minute read

PharmaTher Is ‘One Step Closer To Being A Ketamine Leader’ Due To FDA Acceptance

By Lara Goldstein

September 27, 2:38 PM

The Food and Durg Administration (FDA) has accepted specialty biopharma company PharmaTher Holdings’ (OTCQB: PHRRF) new drug application for a racemic ketamine product.

PHRRF

2 minute read

PharmaTher Aims To Mitigate Ketamine Shortage With New FDA Application

By Lara Goldstein

September 6, 5:21 PM

Specialty biotech company PharmaTher Holdings (OTCQB: PHRRF) reported it has submitted a priority-original Abbreviated New Drug Application (ANDA) for its proprietary racemic ketamine, KETARX, t

PHRRF

2 minute read

Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma’ Nasal Formulation For Ketamine-Based Treatment

By Lara Goldstein

August 8, 4:19 PM

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15.

SILO

2 minute read

Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics

By Lara Goldstein

August 1, 1:09 PM

As part of its business restructuring process and following its London clinics busin

AWKNF

2 minute read

Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets

By Lara Goldstein

June 27, 6:05 PM

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic ketamine KETARX to the FDA.

FTHWF

Feed Tag: Ketamine Treatment